Medicaid

Regeneron agrees with Trump Administration to lower drug prices via Medicaid benchmarking and free gene therapy access, receiving three years of tariff relief and regulatory certainty.

Regeneron offers gene therapy Otarmeni free and Praluent at lower pricing in exchange for tariff relief and exemption from future pricing mandates.

Elevance Health beat Q1 earnings estimates and raised 2026 guidance, but elevated Medicaid costs and a $935M CMS accrual signal underlying margin pressures.

59 million American caregivers drive investment in aging-in-place healthcare stocks as 65+ population set to nearly double by 2060.

ATI Advisory appoints former Wisconsin Medicaid Director Bill Hanna as Practice Director of Payer Strategy, bolstering consulting services for state Medicaid agencies and managed care organizations.